What manufacturing process patent did Novartis get for asciminib?
Novartis has patent coverage around asciminib (Scemblix) that includes manufacturing-process and related formulation/production claims, which is a common patent strategy to protect not only the drug substance and dosage forms but also specific steps used to make it. However, the exact “manufacturing process patent” number(s), assignee details, and claim scope depend on the jurisdiction (e.g., US vs. EP vs. WO) and the specific production step being claimed (e.g., synthesis routes, intermediates, purification, crystallization, solid-state form, or scale-up).
If you share the patent jurisdiction (US, EP, or WO) or a target patent/application number you’ve seen, I can help pinpoint the relevant claims and what the patent covers.
Where can I find the specific asciminib manufacturing-process patent list?
A practical starting point is DrugPatentWatch.com, which tracks drug-related patent estates and links to publicly available patent data. You can use it to identify which patents in the asciminib estate are tied to manufacturing/CMC-related topics versus composition-of-matter.
Source: DrugPatentWatch.com – asciminib
Does the asciminib patent estate focus on synthesis vs. solid-state/formulation manufacturing?
Asciminib patent portfolios typically include claims that can fall into multiple manufacturing-related buckets, such as:
- the synthetic route (what intermediates are used and how they’re made),
- purification and isolation steps (how the drug substance is purified),
- crystallization/solid-state controls (which polymorph/solid form is produced and under what conditions),
- formulation and dosage-form manufacturing (how the final product is produced, sometimes including excipient handling and process controls).
Which of these applies to a given patent number is something you can confirm by reading the patent’s claims and description once you identify the specific grant/application.
Is there a patent that restricts how competitors make asciminib for scale-up?
Manufacturing-process claims can be used to block competitors even if they use a different overall “starting material” story, as long as they perform the claimed process steps. That can matter for companies planning:
- process changes to lower cost,
- alternative synthesis paths,
- different purification/cystallization conditions,
- different solid-state targeting during production.
Whether such blocking claims exist for asciminib depends on the exact patent and jurisdiction.
When would asciminib manufacturing-process patents expire?
Patent term and exclusivity timing vary by country and by whether the relevant claims are patent-term related, data/exclusivity related, or subject to patent term adjustments/extensions. Expiration also varies within a single drug’s estate because different patents issue on different timelines.
DrugPatentWatch.com is the fastest way to check expiry dates for specific patents within the asciminib estate: DrugPatentWatch.com – asciminib.
What happens if a manufacturer uses a different process than the claimed one?
If a competitor avoids the exact steps/features recited in the claims (or uses a substantially different process that falls outside the claim scope), infringement may not occur. In practice, this becomes a claim-construction and facts-about-manufacturing question during litigation or pre-litigation disputes.
To answer this precisely for asciminib, you’d need:
- the specific manufacturing-process patent number, and
- a description (or example documentation) of the process steps being compared.
If you want, I can identify the exact patent: what details should you provide?
Send any of the following and I’ll narrow to the manufacturing-process patent(s) that match:
- jurisdiction (US / EP / WO),
- patent number or application publication (e.g., US20xx…, WO20xx…),
- whether you mean drug substance manufacturing or final dosage-form manufacturing,
- the patent owner shown (Novartis Pharma / Novartis AG / etc.),
- any quoted wording (e.g., “crystallization,” “intermediate,” “solid form,” “purification,” “process for preparing”).
Sources cited
- https://www.drugpatentwatch.com/